Related Experiment Video
Updated: May 21, 2025
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Implantable Cardioverter-Defibrillators for Secondary Prevention in Giant Cell Myocarditis
Krunal Shukla1, Eric J Basile1, Tawfiq Khasawneh1
1Department of Internal Medicine, University of Florida College of Medicine, Gainesville, USA.
Insights
Giant cell myocarditis (GCM) poses challenges for implantable cardioverter-defibrillator (ICD) use in preventing ventricular tachycardia (VT). This case highlights the need for personalized treatment strategies due to limited data on ICDs in GCM patients.
Area of Science:
- Cardiology
- Immunology
- Transplantation
Background:
- Giant cell myocarditis (GCM) is a rare and aggressive inflammatory heart condition.
- Management of ventricular tachycardia (VT) in GCM patients, especially post-heart transplant, remains challenging.
- The role of implantable cardioverter-defibrillators (ICDs) for secondary VT prevention in GCM is not well-defined.
Observation:
- A 42-year-old female with biopsy-proven GCM developed recurrent VT post-orthotopic heart transplantation.
- An ICD was implanted for secondary prevention of VT, subsequently delivering a shock for sustained VT.
- Biopsy confirmed recurrent GCM as the cause of the sustained VT.
Findings:
- The case highlights the lack of standardized guidelines for ICD placement in GCM.
- Limited high-quality data exists regarding the efficacy and safety of ICDs in GCM patients.
- Recurrent GCM can occur post-transplant, necessitating vigilant monitoring and management.
Implications:
- Individualized decision-making is crucial for managing GCM patients requiring arrhythmia control.
- ICDs may play a role in managing life-threatening arrhythmias in both native and recurrent GCM.
- Further research is needed to establish evidence-based guidelines for ICD use in GCM.
Abstract:
Giant cell myocarditis (GCM) presents significant challenges in clinical management, particularly regarding the role of implantable cardioverter-defibrillators (ICDs) for secondary prevention of ventricular tachycardia (VT). We present the case of a 42-year-old female patient with histologically confirmed GCM who underwent orthotopic heart transplantation and subsequently developed VT due to biopsy-proven recurrent GCM within one year after transplant. An ICD was placed for secondary prevention following multiple episodes of monomorphic nonsustained VT. The patient would then present to the hospital for an ICD shock with device interrogation showing one episode of sustained VT. On further work-up, the patient was found to have a biopsy-proven recurrence of GCM. In this context, we review the existing literature, primarily case reports, small case series, and registry data, pertaining to ICD use in GCM. Our case underscores the lack of standardized guidelines and limited high-quality data supporting ICD placement in this population. It highlights the importance of individualized decision-making and contributes to clinical discussions by emphasizing the potential role of ICDs in managing life-threatening arrhythmias associated with both native and recurrent GCM.
More Related Videos
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
